In 2001, Steensma, et al. Increased reticulin and collagen fibrosis may have a prognostic significance that is not accounted for by current prognostic scoring systems. Treatment for myelofibrosis, which focuses on relieving symptoms, can involve a variety of options. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome Brief Report Tiziano Barbui, Jrgen Thiele, Francesco Passamonti, Elisa Rumi, Emanuela Boveri, Maria Luigia Randi, Irene Bertozzi, Filippo Marino, Alessandro M. Vannucchi, Lisa Pieri, Giada Rotunno, Heinz Gisslinger, Bettina Gisslinger, BMF is routinely assessed and graded in core biopsies from patients with a known or suspected MPN, and is a major diagnostic criterion in the 2008 WHO classification system of MPN. Since preliminary analyses had indicated that only MF-3 affected survival, patients with MF-3 were compared with those with MF-02 fibrosis. Stereology and computer-based image analysis quantifies heterogeneity and improves reproducibility for grading reticulin, Bone Marrow. Moreover, the JAK2V617F knock-in megakaryocyte has increased fos gene expression. The changes in grade of BMF at 24 and 48 months of ruxolitinib treatment were analyzed and compared to those in a similar, matched cohort of MF patients treated with hydroxyurea (Table 3). Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Although the exact role of bone morphogenetic proteins in MF is not clear, these studies suggest that they have an integral role in the pathogenesis of BMF.18, Advanced MF is not only typified by BMF, but also by osteosclerosis with an increase and thickening of the bone trabeculae. Fu, et al. Lekovic D, Gotic M, Perunicic-Jovanovic M, et al. Eliades A, Papadantonakis N, Bhupatiraju A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment, DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status, Molecular genetics of myelofibrosis and its associated disease phenotypes, The role of cytokines in the initiation and progression of myelofibrosis, Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro, Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts, The transforming growth factor-beta family, Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-beta, Anti-transforming growth factor beta (TGF-) therapy in patients with myelofibrosis. Furthermore, serum LOX levels were significantly higher in PMF patients than in a control group.93 Simtuzumab is a humanized monoclonal antibody that binds to and inhibits LOXL2. Marisavljevi, et al. Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve? This is achieved by a gain of function in the JH1 domain and loss of function in the auto-inhibitory JH2 domain. They found that BMPR2, SMAD3, and SMAD4 were expressed in both PMF and MDS-F. AskMayoExpert. All rights reserved. Median age was 63 years (range, 32-86 years) and the 5-year OS was 77.1%. Moderate to severe marrow fibrosis as a more advanced risk factor for MDS and MDS-AML patients with excess of blasts receiving allogeneic hematopoietic stem cell transplantation. Among them, one case showed MF-3 levels of fibrosis, whereas 4 cases had MF-1 level fibrosis. Pentraxin (PTX) family proteins include C-reactive protein (CRP; PTX1), serum amyloid P (SAP; PTX2), and pentraxin-3 (PTX3).81 PTX2 is a circulating plasma acute phase response protein made by the liver which localizes to the site of injury and affects monocyte differentiation and function in the removal of damaged tissue. Martinelli G, Oehler VG, Papayannidis C, et al. Reports that address these limitations are scarce to non-existent. showed that patients harboring mutations in any one of the following genes, ASXL1, EZH2, SRSF2 or IDH1/IDH2, have a shorter overall survival and a higher risk of their disease transforming into acute myeloid leukemia compared to MF patients who do not have mutations in any of these genes.40,41 The prognostic impact of mutations in CALR versus JAK2 versus MPL mutations versus triple negativity was assessed in a cohort of 254 patients with PMF. Myelofibrosis biology and contemporary management. All accepted traditional grading systems are dependent on manual grading of reticulin by a histopathologist. Thrombospondin 1 in PMF is thought to be fibrogenic by activating latent TGF-1 and inhibiting metalloproteinases.33,35. As more and more of these mutated cells are created, they begin to have serious effects on blood production. She withdrew from the study 1 month later. Calreticulin (CALR) is a multifunctional calcium-binding protein that is located primarily in the endoplasmic reticulum. Primary myelofibrosis. Bethesda, MD 20894, Web Policies Delayed engraftment post alloSCT has been reported in MDS patients with any degree of BMF [18]. Case 3 A 59-year-old woman with a history of thrombocytopenia for several years, diagnosed as immune thrombocytopenia (ITP) refractory to therapy, developed fevers and night sweats. Phase 1b dose-escalation study of sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis. With the introduction of selective JAK2 inhibitors into clinical investigation over the last 10 years, initial expectation of clonal suppression as measured by elimination of molecular and karyotypic abnormalities was dampened by the observations of persistent clonal hematopoiesis and unaltered MPN bone marrow pathological features. Additionally, patients with a reduction of BMF by 2 or 3 grades at day +100 after HSCT had a trend towards a better overall survival rate than that of patients with unchanged BMF (95% versus 71%, respectively; P=0.19). In primary myelofibrosis (PMF), the higher the fibrosis grade, the poorer the prognosis [5]. The most frequently used grading systems are based on reticulin grade scored using the Bauermeister system from 1971 (04 scale) and the recently revised European consensus system (03 scale) (Table 1 and Figure 1). Several specific gene mutations have been identified in people with myelofibrosis. Myelofibrosis can happen on its own (primary myelofibrosis) or it can develop from another bone marrow disorder (secondary myelofibrosis). [33] studied fibrosis-related gene transcripts in 119 patients with MDS, 70 of whom had accompanying BMF. Finally, in five cases a mild degree of reticulin fibrosis (MF-1) was evident together with an increase in the micro-vessel density. British Journal of Hematology. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial. Reticulin fibrosis is best seen with - not surprisingly - a reticulin stain (which contains silver). Triple negative status and CALR/ASXL+ patients had the shortest median overall survival of 2.5 years and 2.3 years, respectively.36 Low JAK2V617F allele burden at diagnosis, homozygosity for JAK2V617F, as well as elevated levels of IL-8 and/or IL-2R are also associated with worse overall survival.42,43,24 Other molecular markers have also been associated with poor prognosis; however, they have not yet been validated in large prospective studies. For MDS patients with BMF that go on to receive alloSCT, the 3-year relapse rate was higher in patients with BMF than in those without (47% vs. 28%, P=0.04) [34]. sharing sensitive information, make sure youre on a federal Before [24] studied 266 t-MDS patients and reported that monosomy 5 and monosomy 17 were more commonly detected in t-MDS patients with MF-2/3 (P=0.031 and P=0.043, respectively). A major advantage of this approach is that it can provide a measure of heterogeneity of the BMF. 1998-2023 Mayo Foundation for Medical Education and Research (MFMER). As disruption of normal blood cell production increases, signs and symptoms may include: Make an appointment with your doctor if you have any persistent signs and symptoms that worry you. Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features. A phase II trial of simtuzumab monotherapy (stage 1) and combination therapy with ruxolitinib (stage 2) in patients with intermediate-1 or higher risk MF has completed recruitment and the results were recently presented ({"type":"clinical-trial","attrs":{"text":"NCT01369498","term_id":"NCT01369498"}}NCT01369498).94 A total of 24 patients were treated in the stage 1 part of the study and 30 in the stage 2 part, for a minimum median duration of 22 weeks, without a clear signal of response in terms of reduction of BMF. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Bone marrow fibrosis (BMF) is characterized by the increased deposition of reticulin fibers and in some cases collagen fibers. JAK2 signaling is initiated by ligand binding to the cognate cytokine receptor leading to dimerization, which in turn leads to JAK autophosphorylation. The red is a pseudo color that highlights all tissue elements in the bone marrow according to two-photon excitation. AlloSCT is the only potentially curative treatment for MDS. Four images from unstained bone marrow biopsies obtained from patients with myeloproliferative neoplasms with a spectrum of marrow fibrosis ranging from 03 according to the revised European consensus system for grading bone marrow fibrosis. National Comprehensive Cancer Network. Supportive care, immunomodulatory agents, hypomethylating agents, induction chemotherapy, and/or alloSCT can be used. Abbreviation: MDS, myelodysplastic syndrome; BM, bone marrow. However, preclinical and clinical data suggest that hedgehog pathway inhibitors have therapeutic activity in MF. Myelofibrosis in primary myelodysplastic syndromes: a clinico-morphological study of 10 cases. Mild fibrosis (MF-1) is defined as a loose network of reticulin fibers with numerous intersections, particularly in the perivascular areas. Hussein, et al. Before My only question was my BMB also showed mild reticulin fibrosis. HHS Vulnerability Disclosure, Help [27] studied 236 patients with de novo MDS and found that immature cells and blasts in the peripheral blood and BM blasts were more frequently present in patients with MDS-F. As the mutated blood stem cells replicate and divide, they pass along the mutations to the new cells. 2020; doi:10.1111/bjh.16576. Mayo Clinic; 2019. Additionally, osteosclerosis was seen only in mice engrafted with wild-type cells.15, The Gata1low murine model of MF is characterized by normal or mild elevation in TGF-1 levels. Buesche G, Teoman H, Wilczak W, Ganser A, Hecker H, Wilkens L, et al. [25] found that OS was significantly shorter in patients with MF-3 BMF than in those with MF-02 BMF (17 vs. 39.4, 36.6, and 24.5 months, respectively, P<0.005). It is recommended that BMF be integrated into currently used risk classification/stratification systems. In this study, changes in the grade of BMF were determined at 24, 48 and 60 months of ruxolitinib treatment and compared with those in a group of MF patients treated with best available therapy. The .gov means its official. In general, the goals of MF-directed treatment can be divided into two broad categories: clonal eradication and treatments targeting various signaling pathways and mediators implicated in BMF. The median allele burden for the JAK2 Somatic mutations of JAK2, MPL, and CALR behave as founding driver mutations responsible for the MPN phenotype. Narayanan MN, Benaim ME, Geary CG, Harrison CJ. MPN HSC stimulate production of multipotent stromal cells of osteoblastic lineage through cytokines such as thrombopoietin and CCL3, as well as direct cell contact. http://creativecommons.org/licenses/by-nc/4.0. Cox regression analysis revealed that BMF was an independent risk factor for inferior OS and LFS. The most common is the Janus kinase 2 (JAK2) gene mutation. Scott, et al. Studies comparing MDS patients with BMF with those without BMF. In: Hematology: Basic Principles and Practice. utilized a Gata1low mouse model of MF.17 First, the investigators demonstrated that despite normal or mildly elevated plasma concentrations of total and bioactive TGF-1 in PMF patients and Gata-1low mice, the TGF-1 content in megakaryocytes was increased 5- to 10-fold in both. The prognostic impact of BMF should be factored in when deciding on transplant candidacy, especially for intermediate-risk patients. Disrupting the tumor-microenvironment interaction is a potential therapeutic strategy in MPN.28 The effects of disrupting the tumor microenvironment by targeting Eph receptor tyrosine kinases are currently being studied in both solid and hematologic malignancies.100,101 EphA3 is important in cell positioning during fetal development and is not expressed in normal adult tissues. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. compared the pathological changes in irradiated wild-type recipient mice repopulated with thrombopoietin-overexpressing hematopoietic stem cells (HSC) from homozygous TGF-1/ or wild-type littermates.15 Mice engrafted with wild-type and TGF1/ cells developed thrombocytosis, leukocytosis, and increased numbers of progenitor cells in the blood and spleen. In another study including 79 patients with substantial BMF, they noted that the distribution of cytogenetic risk using the new comprehensive cytogenetic scoring system for primary MDS/oligoblastic AML was similar [12]. As discussed above, the IPSS and DIPSS are currently the two commonly used scales to assess prognosis in MF and the prognostication may now be further refined through the incorporation of gene mutation profiling. However, it was discounted as an additive factor for predicting survival in MDS because of its low prevalence and discrepancies in the evaluation of the degree of BMF across institutions. Kvasnicka HM, Thiele J, Schmitt-Graeff A, et al. 9 A few. However, there are several published reports describing reversibility of BMF with interferon- (IFN-) based therapy. Histopathology in Pharmaceutical Product Development. Guglielmelli P, Barosi G, Specchia G, et al. BMF is seen in many hematologic and non-hematologic conditions and is a prominent pathologic feature of MF. The pathogenic role of IL-8 in MF is not yet fully clear, but it may be involved in leukemic transformation through its growth factor and mitogenic activities.25 An increase in IL-2R levels may be a reflection of either immune activation or an increase in tumor cell burden.24. Anti-fibrotic strategies are currently being evaluated in a number of therapeutic trials aimed at disrupting the malignant bone marrow niche and promoting normal over malignant hematopoiesis. Steensma DP, Hanson CA, Letendre L, Tefferi A. Myelodysplasia with fibrosis: a distinct entity? They found that neutrophil engraftment occurred later in patients with MF-1,2/3 than in patients with MF-0 (16 vs. 20 vs. 17 days, P=0.002). Accurate scoring of BMF remains a major area of academic interest and an unmet clinical need. JAK2 is important in mediating the signaling pathways of these cytokines.2, JAK2-signal transducers and activators of transcription (STAT) dysregulation plays a central role in the pathogenesis of MPN. Accessed Dec. 16, 2020. Computer-assisted image analysis correlates well with morphology but was more sensitive than histopathology for detecting BMF level changes in MF patients undergoing treatment.64. Some people with myelofibrosis have no symptoms and might not need treatment right away. Apart from HSCT, none of the conventional therapies utilized in the treatment of MF is considered curative. Risk factors for BMF were prior solid tumor (46.8% vs. 28.3% in prior hematological malignancies) and radiation therapy. However, the clinical significance of this finding and the impact on overall survival of reducing/eliminating BMF with IFN--based therapy remain uncertain. Komroji R does not have any conflicts significant for this review. The technology utilizes the second harmonic generation phenomenon to highlight fibrillar collagen with high specificity as highlighted by the green fluorescent colored structures. Three patients had an increase in plasma cells of more than 5% in peripheral blood, 2 patients had invasion of MM cells into . Ruxolitinib-treated patients who achieved stabilization or improvement in grade of BMF at 24 months had a reduced relative risk of death in this analysis.78. Clinically, patients with moderate to severe BMF had more severe thrombocytopenia (42109/L vs. 62109/L, P=0.039) and tended to have more circulating blasts (P=0.051) than patients with mild BMF, whereas the rates of other clinical symptoms, including anemia, neutropenia, hepatosplenomegaly, transfusion requirements, and constitutional symptoms, were alike. Treatment strategies for patients with MDS heavily rely on prognostic scoring systems, such as the revised international prognostic scoring system (IPSS-R). As the disease progresses, the founding malignant clone acquires additional subclonal mutations. studied patients with MPN and reported that proplatelet numbers were higher in patients with essential thrombocythemia and pre-fibrotic MF than in controls.33 Proplatelets were even more abundant in patients with fibrotic MF compared to those with pre-fibrotic MF or essential thrombocythemia.34 Exaggerated production of proplatelets may be associated with increased thrombospondin production. Elsevier; 2018. https://www.clinicalkey.com. 1 It has also been evaluated in other myeloproliferative neoplasms (MPN), in particular polycythaemia vera, 2, 3 myelodysplastic syndromes 4 - 7 and acute lymphoblastic leukaemia, 8 as well as in non-malignant haematological diseases such as immun. These cytoplasmic tyrosine kinases are associated with transmembrane class receptors of a number of cytokines (e.g. Abdulkarim K, Ridell B, Johansson P, Kutti J, Safai-Kutti S, Andrasson B. This increase is associated with an increase in BMF and trabecular thickening. There are a number of subclonal mutations which have been reported such as those in ASXL1, EZH2, CBL, IDH1/IDH2, TP53 and SRSF2. Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis, Influence of mild bone marrow fibrosis on response of int-2/high risk MDS patients to 5-azacitidine, Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications. Reticulin fibers are an important component of the bone marrow extracellular matrix (ECM) essential for the maintenance of hematopoiesis. Pirfenidone is an anti-fibrotic agent that inhibits fibrogenic cytokines including platelet-derived growth factor, tumor necrosis factor- and TGF- and was studied in 28 patients with MF. Seven patients with MF were included in a phase I study investigating PF-04449913 in myeloid malignancies. Is that normal? As a library, NLM provides access to scientific literature. [9] described 10 cases of primary MDS with striking BMF at presentation. In line with the other MPN subtypes, transformation to AP is defined by 10 to 19% of peripheral blood or bone marrow blasts and frequently associated with progressive splenomegaly and worsening of thrombocytopenia. A number of studies indicate that bone marrow fibrosis is an adverse prognostic variable in myeloproliferative neoplasms. American Journal of Hematology. Cellular / prefibrotic phase is characterized by hypercellularity but absent or minimal reticulin fibrosis MF-0 or 1 (European consensus grading system, Thiele 2005) Peripheral blood may show only marked thrombocytosis Hypercellular marrow Prominent megakaryocytic hyperplasia with dense clustering Increased M:E ratio Pleomorphic megakaryocytes The IPSS-R utilizes cytogenetics, BM blasts, and laboratory parameters, including Hb, platelets, and absolute neutrophil count (ANC), at diagnosis [14]. Importantly the ability of the expanded populations of osteoblastic lineage cells to support normal HSC is compromised, as evidenced by reduced expression of HSC retention factors. Structural fibrils constitute a physiological component of the bone marrow stromal microenvironment and contribute to providing a connective tissue structure and a support for hematopoietic progenitor cells. Two of these patients achieved durable clinical responses (>50% reduction in spleen size) and one patient had a significant reduction in BMF. Buesche G, Ganser A, Schlegelberger B, et al. Historically, BMF has been considered a secondary or reactive process driven by the clonal malignancy and not produced by the malignant cell population itself. In severe or grade 3 fibrosis (MF-3), there can be coarse bundles of collagen (on trichrome stain), frequently accompanying significant osteosclerosis in addition to diffuse and dense reticulin with extensive intersections [17]. MF is characterized by variable degrees of cytopenias, a leukoerythroblastic blood picture, and extramedullary hematopoiesis resulting in progressive splenomegaly and debilitating disease-related constitutional symptoms, compromising quality of life.4,5 In addition to increased disease-related morbidity, MF results in early death with the median survival of affected patients being approximately 6 years.6 Causes of early death include leukemic transformation, complications arising from progressive bone marrow failure, portal/pulmonary hypertension, infections, thrombosis and bleeding.7 Pathologically, MF is characterized by thickening and distortion of bony trabeculae, deposition of reticulin and collagen fibers, and megakaryocytic hyperplasia with atypical features.8, European consensus on the grading of bone marrow fibrosis.1, Conditions associated with bone marrow fibrosis.3. Fluorescence in situ hybridization analysis was performed in only a few patients in this study and none was tested for P53 status. Careful examination of peripheral blood and the slides from bone marrow touch imprint would be helpful. [18] compared patients with MF-3 BMF (N=39) with those with MF-1/2 (N=199) and MF-0 (N=483) BMF. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Bone marrow fibrosis by WHO Grade and quantitative image analysis is reduced by PRM-151 in patients with myelofibrosis and associated with improved bone marrow morphology and increased platelet counts. Verstovsek S, Pozdnyakova O, Hasserjian R, et al. Accessed Dec. 16, 2020. Significance of bone marrow fibrosis in multiple myeloma. 1Department of Hematology and Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, 2Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, 3Hematopathology Division, Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA, 4Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. However, BMF grade was not associated with worse overall survival.52 These results were replicated in another study by Campbell et al. MF-0 or no fibrosis in normal BM is used for patients with scattered linear reticulin without any intersections (cross-overs). The disease presentation described was later included in the category of acute myeloid leukemia (AML), not otherwise specified as acute panmyelosis with myelofibrosis [8]. Serum amyloid P inhibits granulocyte adhesion, Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. Four categories were introduced to simplify the grading of marrow fibrosis (MF). The majority of patients treated with best available therapy received hydroxyurea or various sequential therapies, or were being observed; only a few patients were treated with IFN-. Krger N, Zabelina T, van Biezen A, Brand R, Niederwieser D, Martino R, et al. Higher grade of BMF correlated with clinical manifestations of MF such as lower hemoglobin level, higher percentage of peripheral blood blasts and larger spleen. The MF inflammatory cytokine signature is believed to be both a consequence of the malignant clone as well an integral modifier of the bone marrow microenvironment, thereby, promoting malignant hematopoiesis.9 Transforming growth factor beta (TGF-) is a pleiotropic cytokine that potently stimulates fibroblasts to produce extracellular matrix.1013 It also increases the expression of proteases that inhibit enzymes involved in the degradation of extracellular matrix. They also noted delayed engraftment in patients with BMF (hazard ratio [HR] 0.4; P<0.001). Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Studies in patients with MDS with BMF undergoing BM transplantation. [26] reported that BMF is positively correlated with ferritin and erythropoietin levels, marrow cellularity, abnormal localization of immature precursors (ALIP), packed red blood concentrate transfusions in the first 16 weeks from diagnosis, p53 immunohistochemistry scores, and peripheral Wilms tumor 1 gene expression.